Literature DB >> 26527055

A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.

Joseph Zohar1, Stephen Stahl2, Hans-Jurgen Moller3, Pierre Blier4, David Kupfer5, Shigeto Yamawaki6, Hiroyuki Uchida7, Michael Spedding8, Guy M Goodwin9, David Nutt10.   

Abstract

Neuroscience based Nomenclature (NbN) is a new system of classifying psychotropic drugs by their pharmacological profile. The NbN was developed to replace the current indication-based nomenclature and to provide an up-to-date and more useful framework to better inform pharmacological decisions. NbN provides updated relevant and specific scientific, regulatory and clinical information, aiming to support rational and lucid prescribing. This pharmacologically driven nomenclature, which highlights pharmacological domains and modes of action, may also increase drug adherence as it clarifies the rationale for selecting a specific psychotropic agent.
Copyright © 2015. Published by Elsevier B.V.

Keywords:  Adherence; Mode of action; Neuroscience; Nomenclature; Pharmacological domain; Psychotropic drugs

Mesh:

Substances:

Year:  2015        PMID: 26527055     DOI: 10.1016/j.euroneuro.2015.08.019

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  33 in total

Review 1.  Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.

Authors:  Gin S Malhi; Tim Outhred
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

2.  A new nomenclature for classifying psychotropic drugs.

Authors:  Filippo Caraci; Sam J Enna; Joseph Zohar; Giorgio Racagni; Gil Zalsman; Wim van den Brink; Siegfried Kasper; George F Koob; Carmine M Pariante; Pier Vincenzo Piazza; Kiyofumi Yamada; Michael Spedding; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2017-05-24       Impact factor: 4.335

3.  Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications.

Authors:  Pierre Blier; Maria A Oquendo; David J Kupfer
Journal:  Neuropsychopharmacology       Date:  2017-02-09       Impact factor: 7.853

4.  What do patients learn about psychotropic medications on the web? A natural language processing study.

Authors:  Kamber L Hart; Roy H Perlis; Thomas H McCoy
Journal:  J Affect Disord       Date:  2019-09-10       Impact factor: 4.839

5.  Prescribing according to diagnosis: how psychiatry is different.

Authors:  David Taylor
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

Review 6.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

7.  Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis.

Authors:  Stefan Leucht; Anna Chaimani; Dimitris Mavridis; Claudia Leucht; Maximilian Huhn; Bartosz Helfer; Myrto Samara; Andrea Cipriani; John R Geddes; John M Davis
Journal:  Neuropsychopharmacology       Date:  2019-06-18       Impact factor: 7.853

8.  What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology.

Authors:  Ryan S Sultan; Christoph U Correll; Joseph Zohar; Gil Zalsman; Jeremy Veenstra-VanderWeele
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2018-10       Impact factor: 8.829

Review 9.  Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention.

Authors:  Erica Bell; Phil Boyce; Richard J Porter; Richard A Bryant; Gin S Malhi
Journal:  CNS Drugs       Date:  2021-05-21       Impact factor: 5.749

10.  Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition.

Authors:  Rami Hamati; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2020-05-30       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.